Altre lingue Myriad Genetics, Inc.

Azioni

MYGN

US62855J1043

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 24/04/2024			Variaz. 5gg	Var. 1 gen.
18,63 ^USD	+0,16%		-0,05%	-2,66%

27/02	Transcript : Myriad Genetics, Inc., Q4 2023 Earnings Call, Feb 27, 2024
27/02	Myriad Genetics, Inc. Fornisce una guida alle entrate per il primo trimestre 2024	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

New Myriad Genetics Study Published in Prenatal Diagnosis Shows High Positive Predictive Value for 22q11.2 Microdeletion Syndrome Using Prequel Prenatal Screen	17/04
Nearly Half of Americans Say They’ve Lost Time in Their Lives Due to Poor Mental Health, According to the GeneSight Mental Health Monitor	17/04
New Myriad Genetics Study Published in Prenatal Diagnosis Shows High Positive Predictive Value for 22q11.2 Microdeletion Syndrome Using Prequel® Prenatal Screen	16/04
Myriad Genetics Research Shows Reduction in Hospitalizations for Patients with Depression after GeneSight Testing	09/04
Myriad Genetics Research Shows Reduction in Hospitalizations for Patients with Depression after GeneSight Testing	09/04
Myriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date	22/03
Myriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date	22/03
Myriad Genetics Gets US Patent for SneakPeek Snap Device	20/03
Myriad Genetics Announces Patent Granted for SneakPeek® Snap Device	20/03
Myriad: Q4 Earnings Snapshot	27/02
Earnings Flash (MYGN) MYRIAD GENETICS Reports Q4 EPS $0.04, vs. Street Est of $0.01	27/02
(MYGN) MYRIAD GENETICS Forecasts 2024 Revenue Range $820M - $840M	27/02
Myriad Genetics Reports Strong Fourth Quarter and Full-Year 2023 Financial Results; Fourth Quarter Revenue of $197 Million and Full-Year Revenue of $753 Million Each Grew 11% Year-Over-Year; Delivered GAAP EPS of $(0.36) and Adjusted EPS of $0.04 in the Fourth Quarter 2023; Raising 2024 Revenue Guidance	27/02
Myriad Genetics Reports Strong Fourth Quarter and Full-Year 2023 Financial Results; Fourth Quarter Revenue of $197 Million and Full-Year Revenue of $753 Million Each Grew 11% Year-Over-Year; Delivered GAAP EPS of $(0.36) and Adjusted EPS of $0.04 in the Fourth Quarter 2023; Raising 2024 Revenue Guidance	27/02
Myriad Genetics, Inc. Provides Revenue Guidance for the First Quarter 2024	27/02
Myriad Genetics, Inc. Updates Revenue Guidance for the Fiscal Year 2024	27/02
Myriad Genetics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27/02
Myriad Genetics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	27/02
Myriad Genetics and National Cancer Center Hospital East in Japan Collaborate on Pan-Cancer MRD Monitoring Clinical Trial, SCRUM-MONSTAR-SCREEN-3	27/02
Myriad Genetics to Release Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024	21/02

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Myriad Genetics, Inc.

Azioni

MYGN

US62855J1043

Altre lingue

Filtri